All changes

Semaglutide SOUL trial: study classification corrected from Phase 1–2 to Phase 3

What WPF says today

WPF's semaglutide profile now classifies the SOUL trial (registry NCT03914326; N Engl J Med 2025, PMID 40162642), an oral semaglutide cardiovascular outcomes trial in 9,651 people with type 2 diabetes and cardiovascular or kidney disease, as Phase 3 human evidence. It had been labelled Phase 1–2. The stored evidence-strength grade is unchanged at A (86, provisional), and the trial's results are unchanged.

Semaglutide profile: source record for PMID 40162642 (SOUL) (52202c7e51446e0b3fd46d4144cf9239)

What this change did to the conclusion

Study classification corrected. WPF's record labelled a study with the wrong study type or phase. Only that label changed: the trial's results, the evidence-strength grade WPF had stored and every verdict stayed as they were.

Verdict: unchanged (Not a claim-check change: no claim verdict was involved)

The correction changes the study classification of one source record, from Phase 1–2 to Phase 3. It does not change the stored evidence-strength grade (A, 86, provisional), the grade's rationale, any trial result or any claim-check verdict. The grade is an automated baseline that the pipeline which produced it will recompute later for the corrected tier; if that changes the number, it will be recorded as its own change.

Before and after

Earlier: (the profile record before 2026-11-16)

  • Evidence tier: "Phase 1-2 human evidence" (stored value phase_1_2) for the SOUL publication, PMID 40162642.
  • Evidence-strength grade: A, 86 out of 100, provisional (an automated baseline), with its rationale.

Now: (the profile record from 2026-11-16)

  • Evidence tier: "Phase 3 human evidence" (stored value phase_3) for the same publication.
  • Evidence-strength grade: still A, 86 out of 100, provisional, with the same rationale. The grade was not recomputed by this correction.
  • The trial's results, the publication and the registry record are exactly as they were.

Exact records. Earlier: no separate public address is recorded for the earlier snapshot (it is retained, see the Correction Log entry). Updated: Semaglutide profile (current) · Scholarly export, semaglutide (current).

Where to verify it

Dates

  • Registry record first posted (NCT03914326):
  • Publication (PubMed print date, N Engl J Med 392(20)): . PubMed entered the record on 2025-03-31.
  • Registry results first posted (NCT03914326):
  • WPF verified the source for this change:
  • WPF published the corrected version:

Limits and review status

  • Earlier public snapshots of the profile are retained (Correction Log), but no separate public address for the older snapshot is recorded here; the earlier wording above is the entry's own description of what the record said.
  • The A (86) grade is a provisional automated baseline computed for the earlier tier. This correction does not claim it is the right number for a Phase 3 trial, only that it was not changed.
  • This is a classification correction. It says nothing about whether oral semaglutide works, for whom, or how safe it is.

Review status: AI-assisted source verification. Documented human review: none recorded. This is not scientific review and not attribution to a named reviewer.

Formal record: Correction Log entry.

Cite this change

World Peptide Foundation. "Semaglutide SOUL trial: study classification corrected from Phase 1–2 to Phase 3". Change record semaglutide-soul-phase-3-classification, published 2026-11-16; WPF verified the source on 2026-11-16.
Affected records: 52202c7e51446e0b3fd46d4144cf9239. Change type: Study classification corrected. Before and after: (the profile record before 2026-11-16) to (the profile record from 2026-11-16).
AI-assisted source verification; documented human review: none recorded.
https://www.worldpeptidefoundation.org/research/changes/semaglutide-soul-phase-3-classification